Fig. 1: The AML cell lines CTS and U937 and primary AML patient samples were treated with CX-5461 (CX) or AZD6738 (AZD), alone or in combination, for up to 48 h. | Signal Transduction and Targeted Therapy

Fig. 1: The AML cell lines CTS and U937 and primary AML patient samples were treated with CX-5461 (CX) or AZD6738 (AZD), alone or in combination, for up to 48 h.

From: Simultaneous cotargeting of ATR and RNA Polymerase I transcription demonstrates synergistic antileukemic effects on acute myeloid leukemia

Fig. 1

a, c, j Treated cells were subjected to Annexin V-FITC/PI staining and flow cytometry analyses. b, e, f, i Western blots of whole-cell lysates are shown. Fold changes as determined by densitometry with normalization to β-actin, are displayed below each blot. d Cell cycle progression was determined by propidium iodide staining and flow cytometry analyses. g Chromatin-bound and soluble fractions of RPA32 and γH2AX were analyzed by Western blotting. Fold changes as determined by densitometry, were normalized to histone H4. h Representative visualizations of alkaline comet assays are shown (left panel). The results are plotted as the median percentage of DNA in each comet “tail” of four replicates ± SEM (right panel). * indicates p < 0.01 and *** indicates p < 0.001 (paired two-sample t test). CI: combination index, as determined by using CompuSyn software; cf-caspase 3: cleaved caspase 3; cf-PARP: cleaved PARP

Back to article page